Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Obesity Treatment Coverage topic
No spam. Unsubscribe anytime.
Committee sends obesity‑treatment coverage bill to appropriations after sharp debate over cost and scope
Summary
Senate Bill 48, which would require coverage of obesity treatments including GLP‑1 medications, dietitian visits and bariatric surgery, advanced out of committee after hours of testimony; the state insurance commissioner opposed the bill on premium‑impact grounds and the committee approved it for the Appropriations Committee by a 5‑3 vote.
Senate Bill 48, a broad mandate to require coverage of obesity prevention and treatment services (including FDA‑approved anti‑obesity medications, medical nutrition therapy, behavioral/lifestyle interventions, and bariatric surgery), advanced from the Senate Health and Human Services Committee after extensive testimony and a recorded vote.
Sponsor and supporters described the measure as an effort to treat obesity as a chronic disease and reduce downstream conditions such as type 2 diabetes, heart disease and liver disease. Advocates said coverage would improve access to evidence‑based care and could produce long‑term savings by preventing expensive chronic conditions.
Medical specialists from top Colorado institutions, including obesity medicine physicians and pediatric endocrinologists, testified about clinical benefits and patients’ improved outcomes. Doctor Adam Gildan, an obesity medicine specialist, said anti‑obesity medications are “a tool to help patients improve their eating patterns” and urged the legislature to lead on the issue. Pediatric specialists emphasized that early access for children with severe obesity could prevent progression to adult disease.
The state insurance commissioner, Michael Conway, told the committee that the actuarial analysis his office conducted showed notable premium impacts for commercial markets: the first‑year impact across the individual, small group and large group commercial markets was estimated at roughly $54 million, with multi‑year impacts larger. Conway said the analysis did find some potential medical cost offsets but that premium increases would remain and that the office therefore opposed the bill.
Witnesses for hospitals, health systems and many provider organizations supported coverage but urged careful design. Opposition testimony from employer coalitions, pharmacy benefit managers and some patient advocates focused on the bill’s cost, the rapid growth in utilization of GLP‑1 drugs nationally, and the need to guard against inequitable or coercive use of medications. Several eating‑disorder and size‑diversity advocates told the committee they support treatment access but urged mandatory eating‑disorder screening and stronger informed‑consent protections.
After questions and debate about fiscal impacts and safeguards, the committee voted on SB 48 with a roll call (Carson and Bridal voted no; Cutter excused; Doherty, Judah, Weisman and Michaelson‑Jenae voted yes; Frizzell voted no; the motion carried 5–3). The sponsor said the bill’s actuarial analysis indicates it may be cost‑saving over a long horizon and asked the committee to advance the measure; the committee sent SB 48 to Appropriations with a favorable recommendation.
Why it matters: Newer anti‑obesity drugs have produced rapid clinical uptake and sharp price effects on public and private payers. The committee’s questions focused on how a state coverage mandate would affect premiums, Medicaid, employer costs and long‑term health outcomes.
What’s next: The bill will be considered by the Senate Appropriations Committee for fiscal analysis and budget impact discussion.
